ADALIMUMAB
adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices
ADALIMUMAB (9102C)
9102C
Manner of administration:Injection
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: First continuing treatment
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment - balance of supply
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: Subsequent continuing treatment
